Targeting thyroid cancer with acid-triggered release of doxorubicin from silicon dioxide nanoparticles

Currently, therapy for thyroid cancer mainly involves surgery and radioiodine therapy. However, chemotherapy can be used in advanced and aggressive thyroid cancer that cannot be treated by other options. Nevertheless, a major obstacle to the successful treatment of thyroid cancer is the delivery of drugs to the thyroid gland. Here, we present an example of the construction of silicon dioxide nanoparticles with thyroid–stimulating-hormone receptor-targeting ligand that can specifically target the thyroid cancer. Doxorubicin nanoparticles can be triggered by acid to release the drug payload for cancer therapy. These nanoparticles shrink the tumor size in vivo with less toxic side effects. This research paves the way toward effective chemotherapy for thyroid cancer.

• Publication year

  2017

• Venue

  International Journal of Nanomedicine

• Publication date

  2017-08-21

• Fields of study

  Medicine, Materials Science

• Identifiers
  DOI 10.2147/IJN.S137335PMID 28860762PMCID 5573063
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Nano‐in‐Nano Vector: Merging the Best of Polymeric Nanoparticles and Drug Nanocrystals

  2017cited by this paper
• Core/Shell Nanocomposites Produced by Superfast Sequential Microfluidic Nanoprecipitation.

  2017cited by this paper
• Advances in biodegradable nanomaterials for photothermal therapy of cancer

  2016cited by this paper
• Design of a molecular imprinting biosensor with multi-scale roughness for detection across a broad spectrum of biomolecules.

  2016cited by this paper
• Quantitative real-time detection of carcinoembryonic antigen (CEA) from pancreatic cyst fluid using 3-D surface molecular imprinting.

  2016cited by this paper
• Metal–Organic‐Framework‐Derived Mesoporous Carbon Nanospheres Containing Porphyrin‐Like Metal Centers for Conformal Phototherapy

  2016cited by this paper
• Thyroid-stimulating hormone (TSH)-armed polymer–lipid nanoparticles for the targeted delivery of cisplatin in thyroid cancers: therapeutic efficacy evaluation

  2015cited by this paper
• Genetics of Graves’ Disease: Special Focus on the Role of TSHR Gene

  2015cited by this paper
• Microfluidic assisted one-step fabrication of porous silicon@acetalated dextran nanocomposites for precisely controlled combination chemotherapy.

  2015cited by this paper
• Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma

  2014cited by this paper
• Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes.

  2014cited by this paper
• Microfluidic assembly of monodisperse multistage pH-responsive polymer/porous silicon composites for precisely controlled multi-drug delivery.

  2014cited by this paper
• Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms

  2014cited by this paper
• NIR-triggered anticancer drug delivery by upconverting nanoparticles with integrated azobenzene-modified mesoporous silica.

  2013cited by this paper
• A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery.

  2013cited by this paper
• Well-defined, reversible boronate crosslinked nanocarriers for targeted drug delivery in response to acidic pH values and cis-diols.

  2012cited by this paper
• Photo‐ and pH‐Triggered Release of Anticancer Drugs from Mesoporous Silica‐Coated Pd@Ag Nanoparticles

  2012cited by this paper
• Outpatient Radioiodine Therapy for Thyroid Cancer: A Safe Nuclear Medicine Procedure

  2011cited by this paper
• pH-Sensitive degradable polymersomes for triggered release of anticancer drugs: a comparative study with micelles.

  2010cited by this paper
• A smart flower-like polymeric micelle for pH-triggered anticancer drug release.

  2009cited by this paper
• Tetrapeptide-based hydrogels: for encapsulation and slow release of an anticancer drug at physiological pH.

  2009cited by this paper
• Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice

  2009cited by this paper
• Biodegradable micelles with sheddable poly(ethylene glycol) shells for triggered intracellular release of doxorubicin.

  2009cited by this paper
• G-protein-coupled receptors and cancer

  2007cited by this paper
• Thyroid carcinoma.

  2007cited by this paper
• Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.

  2007cited by this paper
• "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers.

  2006cited by this paper
• Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation.

  2006cited by this paper
• Carcinoma showing thymic‐like elements—a rare malignancy of the thyroid gland

  2004cited by this paper
• Determination of subcutaneous tumor size in athymic (nude) mice

  2004cited by this paper
• Thyroid carcinoma.

  2003cited by this paper
• Overexpression of orphan G‐protein–coupled receptor, Gpr49, in human hepatocellular carcinomas with β‐catenin mutations

  2003cited by this paper
• Doxorubicin-induced apoptosis: Implications in cardiotoxicity

  2002cited by this paper
• Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.

  2000cited by this paper
• Clinically Significant, Isolated Metastatic Disease to the Thyroid Gland

  1999cited by this paper
• Anaplastic Thyroid Carcinoma: Behavior, Biology, and Therapeutic Approaches

  1998cited by this paper
• Metastatic tumors of the thyroid gland: a study of 79 cases in Chinese patients.

  1998cited by this paper
• Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides.

  1995cited by this paper
• Doxorubicin cardiotoxicity: analysis of prevailing hypotheses

  1990cited by this paper
• Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

  1989cited by this paper
• Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.

  1988cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary

  year unknowncited by this paper
• Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry Original Paper Acute Doxorubicin-induced Cardiotoxicity Is Associated with Matrix Metalloproteinase-2 Alterations in Rats Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry

  year unknowncited by this paper

• 5H Pyrolo(3,4-b)Pyrazin-5,7-(6H)-dione 6-(N-Chitosanimide nanoparticle) composite nano silver and encapsulation in γ-cyclodextrin: Synthesis, molecular docking, and biological evaluation for thyroid cancer treatment.

  2025cites this paper
• TSHR in thyroid cancer: bridging biological insights to targeted strategies

  2025cites this paper
• pH-sensitive hyaluronic acid nanomicelles for co-delivery of capsaicin and doxorubicin enhance the treatment of anaplastic thyroid carcinoma.

  2025cites this paper
• Mesenchymal stem cell derived exosomes as Nanodrug carrier of doxorubicin combined with PVT1 siRNA inhibits the progression of gastric cancer.

  2025cites this paper
• Recent advances in nanomedicine for the diagnosis and therapy of thyroid disorders

  2025cites this paper
• Current advance of nanotechnology in diagnosis and treatment for malignant tumors

  2024cites this paper
• Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine

  2024cites this paper
• Surface functionalized nanomaterial systems for targeted therapy of endocrine related tumors: a review of recent advancements

  2024influential citation
• Copper Nanoclusters as Novel Podium for Cancer Detection, Imaging, and Therapy Applications.

  2024cites this paper
• Nanomaterials: a promising multimodal theranostics platform for thyroid cancer.

  2023cites this paper
• Redox/pH-responsive hollow manganese dioxide nanoparticles for thyroid cancer treatment

  2023cites this paper
• Current Application of Nanoparticle Drug Delivery Systems to the Treatment of Anaplastic Thyroid Carcinomas

  2023cites this paper
• Design and synthesis of nano Cu/chitosan-starch bio-composite for the treatment of human thyroid carcinoma

  2022cites this paper
• Scrutinizing the therapeutic and diagnostic potential of nanotechnology in thyroid cancer: Edifying drug targeting by nano-oncotherapeutics

  2021cites this paper
• Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer

  2021cites this paper
• Nanoparticles: Promising Auxiliary Agents for Diagnosis and Therapy of Thyroid Cancers

  2021cites this paper
• Mouse Models of Thyroid Cancer: Bridging Pathogenesis and Novel Therapeutics.

  2020cites this paper
• Understanding the mechanisms of silica nanoparticles for nanomedicine

  2020cites this paper
• Development of stimuli-responsive intelligent polymer micelles for the delivery of doxorubicin

  2020cites this paper
• Cytotoxic effect of silica nanoparticles against hepatocellular carcinoma cells through necroptosis induction.

  2019cites this paper
• Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems

  2019cites this paper
• A local drug delivery system based on visible light-cured glycol chitosan and doxorubicin⋅hydrochloride for thyroid cancer treatment in vitro and in vivo

  2018cites this paper